Department of Neurology, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
Mult Scler. 2018 Jan;24(1):6-11. doi: 10.1177/1352458517738131.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) and a major contributor to disability of young adults in western countries. MS prevalence is highest in areas with low vitamin D. Vitamin D is a fat-soluble compound with numerous physiologic responses, including immune regulation. An increasing volume of work suggests that lower levels of serum vitamin D are associated with an increased risk of MS and a more severe disease course. With the suggestion of a role in MS disease activity, increasing attention is being paid to the potential of using vitamin D as an add-on therapy to established MS disease-modifying therapies. Several preliminary studies have reported results which have shown some promise, but none has yet provided significant evidence of a clinically meaningful improvement. We review our recommendations for off-label supplementation in the context of these findings.
多发性硬化症(MS)是一种中枢神经系统(CNS)的炎症性脱髓鞘疾病,也是导致西方国家年轻成年人残疾的主要原因。MS 的患病率在维生素 D 水平较低的地区最高。维生素 D 是一种脂溶性化合物,具有多种生理反应,包括免疫调节。越来越多的研究表明,血清维生素 D 水平较低与 MS 风险增加和更严重的疾病病程相关。鉴于其在 MS 疾病活动中的作用,人们越来越关注将维生素 D 作为辅助治疗药物,联合用于现有的 MS 疾病修正治疗。一些初步研究报告的结果显示出了一定的前景,但没有一项研究提供了具有临床意义的改善的显著证据。我们在这些研究结果的基础上,对非适应证补充维生素 D 的建议进行了审查。